Amy Quinlan
Net worth: 126 784 $ as of 2026-08-30
Net worth: 126 784 $ as of 2026-08-30
Amy Quinlan is Chief Accounting Officer at Voyager Therapeutics, Inc. since 2026, with employment at the firm starting in 2025.
Formerly, Ms. Quinlan was Vice President-Finance at Vor Biopharma, Inc. from 2024 to 2025 and Vice President & Controller at Tetraphase Pharmaceuticals, Inc. from 2008 to 2020.
Education includes an undergraduate degree from Bryant University.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2026-05-07 | 36,749 ( 0.06% ) | 126 784 $ | 2026-08-30 |
| Companies | Position | Start |
|---|---|---|
| VOYAGER THERAPEUTICS, INC. | Comptroller/Controller/Auditor | 2025-05-07 |
| Companies | Position | End |
|---|---|---|
| VOR BIOPHARMA INC. | Comptroller/Controller/Auditor | 2024-09-29 |
| TETRAPHASE PHARMACEUTICALS, INC. | Comptroller/Controller/Auditor | 2020-07-31 |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 4 |
|---|---|
Tetraphase Pharmaceuticals, Inc.
Tetraphase Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops novel antibiotics | Health Technology |
Bryant University
Bryant University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Voyager Therapeutics, Inc.
Voyager Therapeutics, Inc. BiotechnologyHealth Technology Develops gene therapies for fatal and debilitating diseases of the central nervous system | Health Technology |
Vor Biopharma, Inc.
Vor Biopharma, Inc. BiotechnologyHealth Technology Engages in developing cell therapies | Health Technology |
Select your edition
All financial news and data tailored to specific country editions